FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118230868> ?p ?o ?g. }

• W3118230868 endingPage "126" @default.
• W3118230868 startingPage "119" @default.
• W3118230868 abstract "Objectives Stereotactic Ablative Radiotherapy (SABR) has shown high rates of local control and prolonged survival in early-stage non-small cell lung cancer (NSCLC), though its role in oligometastatic disease is undefined. This study aimed to evaluate SABR as a local consolidative therapy (LCT) in oligometastatic NSCLC patients. Methods In this prospective, single-arm phase 2 trial, we sought to evaluate SABR in patients with stage IV NSCLC, with ≤ five lesions, including the primary tumor. Patients received initial systemic therapy according to international guidelines. Patients without progression after front-line therapy (two months of targeted therapy and ≥ four cycles of chemotherapy) were evaluated by an 18F-FDG-PET/CT to receive consolidative SABR (45−60 Gy in 3–5 fractions) to the primary and all intrapulmonary metastatic sites. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and toxicity. Results A total of 47 patients were included. Mean age was 58.9 years, 59.6 % were female, 87.2 % had adenocarcinoma histology, and the contralateral lung was the main site of metastases in 42.6 %. All patients received systemic front-line therapy, chemotherapy in 61.7 %, and a tyrosine kinase inhibitor (TKI) in 38.3 %. Disease control rate (DCR) and complete metabolic response (CMR) to SABR were 93.6 % and 70.2 %. Median PFS was 34.3 months (95 %CI; 31.1–38.8) for the total cohort; patients with a CMR had a median PFS of 53.9 monthsvs.31.9 months in those without CMR (p = 0.011). Median OS was not reached.Grade 1, 2, and 3 pneumonitis were observed in 79.5 % (31/39), 12.8 % (5/39) and 7.7 % (3/39), respectively. No grade ≥4 toxicities were observed. Conclusion The use of SABR as LCT in oligometastatic NSCLC patients was well tolerated and showed favorable results regarding PFS and OS compared with historical data. The benefit was significantly higher in patients who reached a CMR as assessed by 18F-FDG-PET/CT." @default.
• W3118230868 created "2021-01-05" @default.
• W3118230868 creator A5004226767 @default.
• W3118230868 creator A5008945584 @default.
• W3118230868 creator A5009149972 @default.
• W3118230868 creator A5009931026 @default.
• W3118230868 creator A5028638387 @default.
• W3118230868 creator A5029741791 @default.
• W3118230868 creator A5033440068 @default.
• W3118230868 creator A5035063101 @default.
• W3118230868 creator A5058899614 @default.
• W3118230868 creator A5059846027 @default.
• W3118230868 creator A5071108397 @default.
• W3118230868 creator A5073306873 @default.
• W3118230868 creator A5078452442 @default.
• W3118230868 creator A5084680227 @default.
• W3118230868 date "2021-02-01" @default.
• W3118230868 modified "2023-10-16" @default.
• W3118230868 title "Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study" @default.
• W3118230868 cites W1891507428 @default.
• W3118230868 cites W1969531640 @default.
• W3118230868 cites W1979370876 @default.
• W3118230868 cites W1984005163 @default.
• W3118230868 cites W2040178944 @default.
• W3118230868 cites W2043853087 @default.
• W3118230868 cites W2061653825 @default.
• W3118230868 cites W2115797000 @default.
• W3118230868 cites W2129056013 @default.
• W3118230868 cites W2152393981 @default.
• W3118230868 cites W2536769127 @default.
• W3118230868 cites W2618606899 @default.
• W3118230868 cites W2756478990 @default.
• W3118230868 cites W2761351587 @default.
• W3118230868 cites W2797412423 @default.
• W3118230868 cites W2806810471 @default.
• W3118230868 cites W2807497391 @default.
• W3118230868 cites W2807800408 @default.
• W3118230868 cites W2898504447 @default.
• W3118230868 cites W2911188335 @default.
• W3118230868 cites W2914127251 @default.
• W3118230868 cites W2939770857 @default.
• W3118230868 cites W2944301866 @default.
• W3118230868 cites W2950388470 @default.
• W3118230868 cites W2950580054 @default.
• W3118230868 cites W2954975491 @default.
• W3118230868 cites W2965638931 @default.
• W3118230868 cites W2973095792 @default.
• W3118230868 cites W2981543310 @default.
• W3118230868 cites W2982013504 @default.
• W3118230868 cites W3002238699 @default.
• W3118230868 cites W3019546741 @default.
• W3118230868 cites W4210992155 @default.
• W3118230868 doi "https://doi.org/10.1016/j.lungcan.2020.12.029" @default.
• W3118230868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33385737" @default.
• W3118230868 hasPublicationYear "2021" @default.
• W3118230868 type Work @default.
• W3118230868 sameAs 3118230868 @default.
• W3118230868 citedByCount "16" @default.
• W3118230868 countsByYear W31182308682021 @default.
• W3118230868 countsByYear W31182308682022 @default.
• W3118230868 countsByYear W31182308682023 @default.
• W3118230868 crossrefType "journal-article" @default.
• W3118230868 hasAuthorship W3118230868A5004226767 @default.
• W3118230868 hasAuthorship W3118230868A5008945584 @default.
• W3118230868 hasAuthorship W3118230868A5009149972 @default.
• W3118230868 hasAuthorship W3118230868A5009931026 @default.
• W3118230868 hasAuthorship W3118230868A5028638387 @default.
• W3118230868 hasAuthorship W3118230868A5029741791 @default.
• W3118230868 hasAuthorship W3118230868A5033440068 @default.
• W3118230868 hasAuthorship W3118230868A5035063101 @default.
• W3118230868 hasAuthorship W3118230868A5058899614 @default.
• W3118230868 hasAuthorship W3118230868A5059846027 @default.
• W3118230868 hasAuthorship W3118230868A5071108397 @default.
• W3118230868 hasAuthorship W3118230868A5073306873 @default.
• W3118230868 hasAuthorship W3118230868A5078452442 @default.
• W3118230868 hasAuthorship W3118230868A5084680227 @default.
• W3118230868 hasConcept C106159729 @default.
• W3118230868 hasConcept C126322002 @default.
• W3118230868 hasConcept C143998085 @default.
• W3118230868 hasConcept C162324750 @default.
• W3118230868 hasConcept C168563851 @default.
• W3118230868 hasConcept C187625094 @default.
• W3118230868 hasConcept C203092338 @default.
• W3118230868 hasConcept C2776256026 @default.
• W3118230868 hasConcept C2776694085 @default.
• W3118230868 hasConcept C2780739268 @default.
• W3118230868 hasConcept C509974204 @default.
• W3118230868 hasConcept C71924100 @default.
• W3118230868 hasConcept C85393063 @default.
• W3118230868 hasConcept C91602232 @default.
• W3118230868 hasConceptScore W3118230868C106159729 @default.
• W3118230868 hasConceptScore W3118230868C126322002 @default.
• W3118230868 hasConceptScore W3118230868C143998085 @default.
• W3118230868 hasConceptScore W3118230868C162324750 @default.
• W3118230868 hasConceptScore W3118230868C168563851 @default.
• W3118230868 hasConceptScore W3118230868C187625094 @default.
• W3118230868 hasConceptScore W3118230868C203092338 @default.
• W3118230868 hasConceptScore W3118230868C2776256026 @default.

• next